Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04598724
  4. Details
NCT04598724 Clinical Trial

Addressing Barriers to Palliative Care Use in Bladder Cancer

Muscle-Invasive Bladder Carcinoma Clinical Trial

Official title:
Addressing Barriers to Palliative Care Use in Bladder Cancer Through Better Understanding of Knowledge and Belief Development

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04598724
Other study ID # MCC-20809
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 22, 2020
Est. completion date May 10, 2021

Study information
Verified date December 2022
Source H. Lee Moffitt Cancer Center and Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Investigators plan to establish an in-depth understanding of knowledge and beliefs about palliative care in advanced Bladder Cancer patients and their caregivers, and to identify factors associated with positive and negative experiences with palliative care services among those who have received them.

Recruitment information / eligibility
Status Completed
Enrollment 54
Est. completion date May 10, 2021
Est. primary completion date May 10, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Eligibility for both patient and caregiver participants will include: - age =18 years - able to speak and read English - cognitively able to participate in study tasks - willing to participate in surveys, semi-structured interviews, and/or focus groups - able to participate in either a Zoom meeting or phone interview - able to complete an emailed or paper survey - Patient Participants: a diagnosis of muscle-invasive or locally advanced bladder cancer (stages II-IV). Exclusion Criteria: - Patients and caregivers will be excluded if unable to provide verbal or written consent

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Surveys
Survey will be administered involving questions regarding knowledge and perception of palliative care.

Locations
Country Name City State
United States Moffitt Cancer Center Tampa Florida

Sponsors (1)
Lead Sponsor Collaborator
H. Lee Moffitt Cancer Center and Research Institute

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Development of palliative care knowledge and beliefs Thematic analysis of interviews transcriptions to identify the themes that underpin the development of palliative care beliefs among patients with muscle invasive bladder cancer. 12 Months
Primary Proportion with accurate palliative care knowledge and beliefs Proportion of patients correctly answering each palliative care knowledge question. 12 Months
Secondary Association between Bladder Cancer stage and palliative care knowledge Analysis of variance calculated for the mean number of subjects with each cancer stage correctly answering each palliative care knowledge question 12 Months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05097404 - Clinical Utility of VI-RADS in Diagnosis of MIBC
Recruiting NCT05483868 - A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer Phase 1
Not yet recruiting NCT04966130 - Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.
Active, not recruiting NCT04610671 - Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC Phase 1
Recruiting NCT06341400 - RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients Phase 1/Phase 2
Recruiting NCT05203913 - Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT05790850 - Pre-Habilitation With Mindfulness and Exercise for Patients Undergoing Radical Cystectomy (PRIMER Trial) N/A
Recruiting NCT05295992 - Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach N/A
Recruiting NCT06215976 - The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer Phase 4
Recruiting NCT05028660 - AURORAX-0093A: Glycosaminoglycan Profiling for Prognostication of Muscle-invasive Bladder Cancer - a Pilot Study
Not yet recruiting NCT04909775 - Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer Phase 2
Recruiting NCT04876313 - An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) Phase 2
Not yet recruiting NCT04686149 - a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer Patients
Active, not recruiting NCT05630131 - ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
Recruiting NCT06170177 - Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy
Terminated NCT05221827 - Clinical Performance Evaluation of the C2i-Test
Recruiting NCT06257017 - Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial Phase 2
Recruiting NCT05767528 - Clinical Study of Neoadjuvant Therapy Outcome Prediction of Muscle-invasive Bladder Cancer Based on PTC Drug Sensitivity Detection
Recruiting NCT05975307 - Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation Phase 2
Suspended NCT04506554 - A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer Phase 2

External Links